Published in Br J Cancer on December 05, 2006
The evolving biology and treatment of prostate cancer. J Clin Invest (2007) 1.81
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Behavioral stress accelerates prostate cancer development in mice. J Clin Invest (2013) 1.52
The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br J Pharmacol (2010) 1.30
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett (2007) 1.20
Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther (2011) 1.10
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br J Cancer (2014) 1.06
New roles of G protein-coupled receptor kinase 2 (GRK2) in cell migration. Cell Adh Migr (2009) 1.01
Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer (2013) 0.95
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Prognostic prostate tissue biomarkers of potential clinical use. Virchows Arch (2014) 0.95
Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer (2010) 0.90
Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med (2012) 0.85
Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxid Med Cell Longev (2013) 0.84
Resolving tumor heterogeneity: genes involved in chordoma cell development identified by low-template analysis of morphologically distinct cells. PLoS One (2014) 0.82
Growth inhibition of human hepatocellular carcinoma cells by overexpression of G-protein-coupled receptor kinase 2. J Cell Physiol (2012) 0.80
What is the molecular pathology of low-risk prostate cancer? World J Urol (2008) 0.79
Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT. Medicine (Baltimore) (2016) 0.77
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Seven-transmembrane receptors. Nat Rev Mol Cell Biol (2002) 11.50
Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 9.40
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer (2003) 3.96
Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 3.83
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer (2001) 2.17
Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res (2003) 1.83
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol (1996) 1.68
Prostate cancer diagnosis and management. Lancet (1997) 1.68
Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer (2002) 1.65
Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem (2004) 1.64
High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol (2003) 1.57
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem (2002) 1.44
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol (2002) 1.43
Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie (2003) 1.26
Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem (2005) 1.26
Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer (2002) 1.15
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Constitutively active protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells. Curr Biol (1997) 1.11
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity. Oncogene (2001) 1.09
Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer (2001) 1.07
High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol (2004) 1.01
High levels of nm23 expression are related to cell proliferation in human prostate cancer. Cancer Res (1994) 1.01
Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate (1999) 1.00
Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J Cancer Res (1993) 0.98
Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw (2000) 0.90
Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer. Eur Urol (2002) 0.87
Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization. Eur Urol (2002) 0.85
Combined study of prostatic carcinoma by classical cytogenetic analysis and comparative genomic hybridization. Int J Oncol (2001) 0.78
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer (1997) 8.27
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12
Role of chromosome territories in the functional compartmentalization of the cell nucleus. Cold Spring Harb Symp Quant Biol (1993) 3.38
Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut (2010) 3.24
Isolation of peroxisome-deficient mutants of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1989) 2.80
Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet (1993) 2.64
Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes. Hum Genet (1988) 2.52
Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res (1998) 2.41
Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome. Proc Natl Acad Sci U S A (1990) 2.29
Active and inactive genes localize preferentially in the periphery of chromosome territories. J Cell Biol (1996) 2.25
Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney Int (2008) 2.21
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res (2000) 2.09
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08
Molecular characterization of a slowly gating human hyperpolarization-activated channel predominantly expressed in thalamus, heart, and testis. Proc Natl Acad Sci U S A (1999) 2.07
The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J Cell Sci (1998) 1.92
Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood (1996) 1.85
DNA microarray analysis identifies candidate regions and genes in unexplained mental retardation. Neurology (2007) 1.81
Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene (1998) 1.81
Chromosomal in situ suppression hybridization of human gonosomes and autosomes and its use in clinical cytogenetics. Hum Genet (1990) 1.81
Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int (2006) 1.80
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A (1997) 1.76
Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res (1998) 1.75
Quantitative analysis of comparative genomic hybridization. Cytometry (1995) 1.72
Evidence for a nuclear compartment of transcription and splicing located at chromosome domain boundaries. Chromosome Res (1993) 1.72
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet (2001) 1.70
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood (1997) 1.69
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol (2001) 1.68
Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res (1998) 1.68
The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product. Genomics (1990) 1.67
Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res (1996) 1.63
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62
Laparoscopic restorative proctocolectomy. Br J Surg (2005) 1.60
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer (2005) 1.59
Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood (1999) 1.55
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res (2001) 1.51
High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood (1994) 1.50
Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer (2001) 1.49
S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol (1999) 1.49
Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol (1999) 1.48
De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene (2010) 1.47
Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A (2000) 1.46
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood (1996) 1.46
Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol (2006) 1.45
Clustered arrangement of winged helix genes fkh-6 and MFH-1: possible implications for mesoderm development. Development (1996) 1.44
Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer (1998) 1.42
Breakpoints of Burkitt's lymphoma t(8;22) translocations map within a distance of 300 kb downstream of MYC. Genes Chromosomes Cancer (1994) 1.40
Wnt pathway regulation in chronic renal allograft damage. Am J Transplant (2009) 1.39
[Obsessive compulsive disorder and the internet. An evaluation of Dutch-language websites and quality indicators]. Tijdschr Psychiatr (2006) 1.39
Genomic imbalances are rare in hairy cell leukemia. Genes Chromosomes Cancer (1999) 1.39
Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc Natl Acad Sci U S A (1992) 1.38
Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood (1998) 1.36
Nuclear envelope and chromatin compositional differences comparing undifferentiated and retinoic acid- and phorbol ester-treated HL-60 cells. Exp Cell Res (2001) 1.35
Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem (2000) 1.35
Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol (1995) 1.34
Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia (2002) 1.33
Primary structure and function of a second essential member of the heterooligomeric TCP1 chaperonin complex of yeast, TCP1 beta. Proc Natl Acad Sci U S A (1994) 1.32
Acupuncture and Chinese herbal medicine in the treatment of patients with seasonal allergic rhinitis: a randomized-controlled clinical trial. Allergy (2004) 1.28
Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J (1999) 1.28
Chromosomal localization of the four genes (NFIA, B, C, and X) for the human transcription factor nuclear factor I by FISH. Genomics (1995) 1.27
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol (2001) 1.27
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant (2005) 1.27
Partial characterization of the human beta-myosin heavy-chain gene which is expressed in heart and skeletal muscle. Eur J Biochem (1986) 1.24
Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer (1998) 1.23
Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer (2000) 1.23
CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer (2001) 1.23
Retinoic acid differentiation of HL-60 cells promotes cytoskeletal polarization. Exp Cell Res (2000) 1.23
Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization. Am J Pathol (1998) 1.22
Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer (2000) 1.22
Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol (1998) 1.22
Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med (Berl) (1999) 1.21
Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet (1997) 1.21
High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer (2008) 1.20
On the prognostic value of survival models with application to gene expression signatures. Stat Med (2010) 1.20
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene (2011) 1.20
Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood (1997) 1.19
[Aspirations of medical students: "planning for a secure career" - results of an online-survey among students at five medical schools in Germany]. Dtsch Med Wochenschr (2011) 1.19
Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene (2006) 1.19
Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer. Ann Surg (2000) 1.18
Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. Proc Natl Acad Sci U S A (1997) 1.17
Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res (1997) 1.17
Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Hum Genet (1993) 1.16
Antibiotics in urinary-tract infections. Sustained change in prescribing habits by practice test and self-reflection: a mixed methods before-after study. BMJ Qual Saf (2011) 1.16
Association of pKi-67 with satellite DNA of the human genome in early G1 cells. Chromosome Res (1998) 1.16
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia (2010) 1.15
Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med (1997) 1.13